Radiopharmaceuticals testing expertise

Pharmatest has over a decade of experience in testing efficacy of targeted radionuclide therapy studies in preclinical efficacy models. We have performed a large amount of studies and developed a specialized understanding for testing alpha emitters such as pioneering work with the first targeted alpha therapy Radium-223 dichloride (Ra-223), Ra-224, Th-227, Ac-225 and Lu-177.  

We offer a comprehensive suite of targeted radionuclide therapy services including in vitro testing, ex vivo models and rodent in vivo models. 

Our in vivo models include subcutaneous, orthotopic and metastatic models. Many of our routinely used techniques such as hematology, serum biomarker analysis and histology can be performed with radioactive samples. For our radionuclide therapy animal studies, we leverage a range of high-resolution imaging techniques such as bioluminescence imaging, MicroCT, pQCT and DXA. 

We can label your radioactive compounds for example with antibody conjugates and confirm the radiolabeling efficiency using basic methods. 

Many of our studies have been published in highly ranked scientific journals and as poster presentations in leading scientific events.

Below you can find selected publications from studies performed at Pharmatest: 

Our modernly equipped laboratories meet stringent safety standards and have been certified by the Radiation and Nuclear Safety Authorities in Finland. We hold licenses for handling radioactive materials within our facility, ensuring the utmost safety and compliance.  

Our services extend to the shipment of your compound, and we can also arrange the shipment of radioactive samples collected during the study to our clients for further analysis. 

Contact an Expert